At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 425 enrolled
Drug / intervention
Atorvastatindrug
Likely dose
Atorvastatin 40mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Eight-Week Treatment, Single-Step Titration Open-Label Study Assessing The Percentage Of Korean Dyslipidemic Patients Achieving LDL Cholesterol Target With Atorvastatin Starting Doses Of 10 MG, 20 MG, And 40 MG.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·interventional·Posted Oct 8, 2007·Updated Mar 12, 2021
In Brief
A Phase 4 clinical trial evaluating Atorvastatin for Dyslipidemias. Completed, enrolled 425 participants across 20 sites.
Detailed Summary
To evaluate the percentage of Korean dyslipidemic subjects in the total group and each cardiovascular risk group achieving LDL-C target as defined by NCEP ATP Ⅲ criteria at starting doses of 10mg, 20mg and 40mg of atorvastatin after 8 weeks of treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDyslipidemias
CountriesSouth Korea
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2007
First PostedOct 2007
Primary CompletionMay 2008
TodayJul 2026
First PostedOct 8, 2007
Enrollment StartOct 1, 2007
Primary CompletionMay 1, 2008
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 18.7 years ago
Interventions
Atorvastatindrug
Prescription of 10/20/40mg dose atorvastatin based on the personal risk factor that is defined in the NCEP ATP III guideline in a single patient group